Textiles Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Textiles Press Releases.

Press releases published on April 17, 2026

Apr. 17, 2026

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Indeterminate GlobeNewswire

Apr. 17, 2026

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

Indeterminate GlobeNewswire

Apr. 17, 2026

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

Indeterminate GlobeNewswire

Apr. 17, 2026

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Indeterminate GlobeNewswire

Apr. 17, 2026

Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Indeterminate GlobeNewswire

Apr. 17, 2026

New Era Energy & Digital Announces Appointment of Andy Casazza as Chief Corporate Officer

Indeterminate GlobeNewswire

Apr. 17, 2026

Genesis Revival Claims Evaluated: Analyzing the Pineal Gland Support Ingredients, Side Effects Risk and User Complaints

Indeterminate GlobeNewswire

Apr. 17, 2026

NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET

Indeterminate GlobeNewswire

Apr. 17, 2026

Introspect Technology Adds New ATE-on-Bench Solution for LPDDR6, DDR6, and HBM Interfaces

Indeterminate GlobeNewswire

Apr. 17, 2026

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Indeterminate GlobeNewswire

Apr. 17, 2026

Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial

Indeterminate GlobeNewswire

Apr. 17, 2026

Brazilian Wood Claims Evaluated: Discover the Male Enhancement Hardening Pill Truth by SuperNatural Man

Indeterminate GlobeNewswire

Apr. 17, 2026

Kairos Power Breaks Ground on Hermes 2 Demonstration Plant

Indeterminate GlobeNewswire

Apr. 17, 2026

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

Indeterminate GlobeNewswire

Apr. 17, 2026

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026

Indeterminate GlobeNewswire

Apr. 17, 2026

New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma

Indeterminate GlobeNewswire

Apr. 17, 2026

Pheast Therapeutics Reports Initial Phase 1a Data Showing Early Clinical Activity and Target Engagement for PHST001 at AACR 2026

Indeterminate GlobeNewswire

Apr. 17, 2026

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Indeterminate GlobeNewswire

Apr. 17, 2026

Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting

Indeterminate GlobeNewswire

Apr. 17, 2026

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

Indeterminate GlobeNewswire